Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daptomycin plus fosfomycin versus daptomycin alone for MRSA bacteremia
2013-000586-37Phase 3Active
- Sponsor
- RemAb Therapeutics
- Start
- May 2013
- Modality
- Small Molecules, Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial in Staphylococcal bacteremia comparing Daptomycin + fosfomycin with Daptomycin monotherapy (2 arms). Primary endpoints: Primary: therapy response and Primary timing. Started May 2013; status: active.
02
Drugs
daptomycinfosfomycin
03
Conditions
Staphylococcal bacteremia
Beyond the preview
Go deeper on 2013-000586-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000586-37.